NCT03701555View on ClinicalTrials.gov

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

January 31, 2021

Study Completion Date

July 2, 2021

Conditions
Digestive System Disease
Interventions
OTHER

PvP001 placebo

placebo

DRUG

PvP001 100 mg

PvP001 100 mg

DRUG

PvP001 300 mg

PvP001 300 mg

DRUG

PvP001 900 mg

PvP001 900 mg

DRUG

Maximum Feasible Dose (MFD) of PvP002

MFD of PvP002

DRUG

Maximum Tolerated Dose (MTD) of PvP001

Maximum Tolerated Dose (MTD) of PvP001

DRUG

MTD of PvP001 following 7 days of PPI treatment

Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment

OTHER

PvP002 placebo

Placebo

DRUG

PvP001 600 mg

PvP001 600 mg

DRUG

PvP003 placebo

Placebo tablet orally.

DRUG

PvP003

PvP003 tablet orally.

DRUG

PvP003 150 mg

PvP003 150 mg

Trial Locations (1)

92801

Anaheim Clinical Trials, Anaheim

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY